PRF Technologies Ltd. (PRFX)
NASDAQ: PRFXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PRFX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.66M
- EPS (TTM)
- -$4.09
- Dividend yield
- None
- 52-week range
- 0.46 – 7.95
- Day range
- 0.46 – 0.6005
- Volume / Avg
- 69.82K / 228.55K
- Beta
- —
- Shares outstanding
- 3.50M
52-week range
PRFX stock today
Shares of PRF Technologies (PRFX) finished lower on Nov 20 at $0.4758, a drop of 23.68% or $0.1476 per share, versus the S&P 500's 3.70% decline. Trading was light, with 69.82K shares changing hands, about 31% of the average daily volume. At this level, PRFX sits near the bottom of its 52-week range of $0.46 to $7.95: 94.0% below the high and 3.4% above the low.
PRF Technologies has posted a net loss over the last twelve months (EPS of -$4.09), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About PRF Technologies
Company profilePRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company was formerly known as PainReform Ltd.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Efraim Cohen-Arazi
- Headquarters
- Tel Aviv
- Employees
- 6
- IPO year
- 2020
- Website
- painreform.com
Financial highlights
Full financialsIn fiscal 2025, PRF Technologies generated $17,000 in revenue, up 0.0% from fiscal 2024. PRF Technologies reported a net loss of $5.0 million, compared with a loss of $14.6 million a year earlier. Gross margin was -311.8% and operating margin -30129.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $17.00K | $0 | $0 | — | — |
| Growth | — | — | — | — | — |
| Net income | $-5.02M | $-14.59M | $-9.34M | $-8.79M | $-7.25M |
| EPS (diluted) | $-7.47 | $-105.52 | $-122.94 | $-63.46 | $-7.25 |
PRFX news
All PRFX news- PRF Technologies and Dotz Nano Sign Term Sheet for Strategic Collaboration to Expand AI-Driven Energy Optimization OfferingGlobeNewswire
- PRF Technologies Issues Letter to Shareholders Highlighting $11.0 Million Cash Position, Entering Phase 2 Trial of OcuRing™-K and GridFeed™ Opportunity in AI Data Center PowerGlobeNewswire
PRF Technologies peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| JUNSJupiter Neurosciences Inc. | 1.24 | -18.75% | $1.63M | vs PRFX |
| KALAKALA BIO Inc. | 2.71 | -10.28% | $1.74M | vs PRFX |
| SBFMSunshine Biopharma Inc. | 2.23 | -5.11% | $1.84M | vs PRFX |
| PPBTPurple Biotech Ltd. ADR | 1.53 | -4.09% | $1.86M | vs PRFX |
| PPCBPropanc Biopharma Inc. | 1.78 | +3.19% | $1.87M | vs PRFX |
| XRTXXORTX Therapeutics Inc. | 0.839 | -5.73% | $1.88M | vs PRFX |
| EOCNEocene Ltd. | 1.78 | +1.73% | $1.90M | vs PRFX |
| APVOAptevo Therapeutics Inc. | 0.4041 | -2.37% | $1.40M | vs PRFX |
Indexes, lists and sector
PRF Technologies stock FAQ
What is PRF Technologies's stock price today?
PRFX last traded at $0.4758 as of Nov 20, 4:00 PM EST, down 23.68% on the day. Prices are delayed at least 15 minutes.
Who is PRF Technologies's CEO?
Mr. Efraim Cohen-Arazi is the chief executive officer of PRF Technologies Ltd., which has about 6 employees.
What is the PRFX 52-week high?
The 52-week high for PRFX is $7.95 and the 52-week low is $0.46. The stock is currently 94.0% below its high.